First Turn Management LLC Takes Position in Guardant Health, Inc. $GH

First Turn Management LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, Holdings Channel.com reports. The firm purchased 271,685 shares of the company’s stock, valued at approximately $27,750,000. Guardant Health comprises 3.2% of First Turn Management LLC’s portfolio, making the stock its 16th biggest holding.

Other large investors have also made changes to their positions in the company. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the fourth quarter valued at approximately $35,000. Finally, Parallel Advisors LLC raised its holdings in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after acquiring an additional 219 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

Guardant Health stock opened at $131.62 on Friday. The firm has a market cap of $17.45 billion, a PE ratio of -38.83 and a beta of 1.61. The firm’s 50 day moving average price is $103.51 and its two-hundred day moving average price is $102.14. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $134.28.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Guardant Health in a report on Thursday. They set an “outperform” rating and a $185.00 price target on the stock. Piper Sandler set a $127.00 price target on shares of Guardant Health in a report on Thursday, May 21st. Guggenheim lowered shares of Guardant Health from a “buy” rating to a “buy” rating in a report on Thursday, May 28th. Mizuho upped their price objective on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Finally, Stifel Nicolaus upped their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $141.95.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the transaction, the director owned 11,183 shares in the company, valued at approximately $1,420,017.34. This represents a 47.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the completion of the transaction, the insider owned 45,950 shares in the company, valued at approximately $4,894,134.50. This represents a 30.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 452,238 shares of company stock worth $51,425,612. 5.60% of the stock is owned by company insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.